
1. Initial assessment
Consider PE in unexplained breathlessness, pleuritic chest pain, syncope, haemoptysis, tachycardia or hypoxia.
Assess ABCDE, observations and haemodynamic stability. Obtain ECG and CXR where appropriate; neither excludes PE.
HAEMODYNAMICALLY UNSTABLE → HIGH-RISK PE
Cardiac arrest, obstructive shock or persistent hypotension (SBP <90 mmHg or fall ≥40 mmHg for >15 minutes, not otherwise explained).
- Immediate senior ED and critical care involvement.
- Resuscitate, provide oxygen and avoid excessive IV fluids in RV failure.
- Urgent CTPA if feasible; bedside echo if too unstable for transfer.
- Consider IV unfractionated heparin and urgent reperfusion, including systemic thrombolysis.
Do not delay emergency treatment for Wells, PERC or D-dimer.
2. Stable patient – Diagnostic pathway
PERC – Very low clinical suspicion only
Use PERC only when clinical suspicion is low and an alternative diagnosis is feasible. (Pre-test probability must be <15%)
All eight must be negative:
| PERC Criterion | Required finding |
|---|---|
| Age | <50 years |
| Heart rate | <100/min |
| SpO₂ | ≥95% on room air |
| Unilateral leg swelling | Absent |
| Haemoptysis | Absent |
| Recent surgery or significant trauma requiring hospitalisation | Absent |
| Previous DVT/PE | Absent |
| Exogenous hormone use | Absent |
All negative: PE may be excluded without further testing in an appropriately selected patient.
Any positive or ongoing suspicion: calculate Wells.
Two-level Wells score
| Wells Clinical Feature | Points |
|---|---|
| Clinical DVT signs (leg swelling and deep vein tenderness) | 3 |
| Alternative diagnosis less likely than PE | 3 |
| Heart rate >100/min | 1.5 |
| Immobilisation >3 days or surgery within 4 weeks | 1.5 |
| Previous DVT/PE | 1.5 |
| Haemoptysis | 1 |
| Active/recent malignancy (treatment within 6 months or palliative) | 1 |
Wells >4 – PE likely: CTPA. Do not use D-dimer to exclude PE. Give interim therapeutic anticoagulation if imaging cannot be performed immediately, unless contraindicated.
Wells ≤4 – PE unlikely: D-dimer using CHFT thresholds. If results cannot be obtained within 4 hours, offer interim therapeutic anticoagulation unless contraindicated.
D-dimer – DDU assay thresholds
| Age | Negative if |
|---|---|
| <50 years | <230 ng/L |
| ≥50 years | <5 × age in years (ng/L) |
Examples: 50 years <250; 60 <300; 70 <350; 80 <400; 90 <450.
- Below threshold: PE excluded in the appropriate clinical context.
- At or above threshold: imaging required.
Use only the locally validated assay and reporting units.
Imaging: CTPA first line
- If imaging is delayed, offer interim therapeutic anticoagulation unless contraindicated.
- Heparin 80unit/kg OR treatment dose Tinzaparin – (Give Prior to Urgent CTPA)
- Consider V/Q imaging if CTPA is unsuitable (e.g. selected patients with severe renal impairment or contrast allergy).
- Consider U/S if evident DVT
For stable patients requiring investigation, calculate sPESI to assess potential suitability for SDEC.
| sPESI criterion | Points |
|---|---|
| Age >80 years | 1 |
| History of cancer | 1 |
| Chronic heart failure or lung disease | 1 |
| Heart rate ≥110/min | 1 |
| SBP <100 mmHg | 1 |
| SpO₂ <90% | 1 |
- sPESI = 0 → Consider SDEC ensure referred and treated (mSDEC will contact patient with a time to attend)
- sPESI ≥1 → Senior review, ED investigation or admission will be considered
- If imaging is delayed, offer interim therapeutic anticoagulation unless contraindicated.
3. Risk Stritification
| Risk | Features | Management |
|---|---|---|
| High | Cardiac arrest, shock or persistent hypotension | Critical care, urgent reperfusion assessment |
| Intermediate-high | Stable BP, elevated clinical risk (PESI III–V or sPESI ≥1), RV dysfunction and positive troponin | Monitored admission, anticoagulation, senior/critical care review |
| Intermediate-low | Stable BP, increased clinical risk and/or RV injury markers without meeting intermediate-high criteria | Anticoagulation, reassessment and appropriate monitoring |
| Low | Stable, usually sPESI 0, no concerning RV injury markers | Consider SDEC/ambulatory treatment |
4. Confirmed PE – Treatment
Low/Intermediate Risk – Anticoagulation
- Apixaban or rivaroxaban first-line for most suitable patients.
- Alternative anticoagulation may be needed in pregnancy, severe renal impairment, contraindications or selected cancer-associated VTE.
- Check FBC, renal function, LFTs and coagulation screen; do not delay necessary treatment solely while awaiting results.
- Treat confirmed PE for at least 3 months, then reassess duration.
High Risk – Thrombolysis decision
High-risk PE with a pulse
Actilyse (alteplase) – UK licensed regimen
| Weight | IV bolus | IV infusion | Total |
|---|---|---|---|
| ≥65 kg | 10 mg over 1–2 min | 90 mg over 2 h | 100 mg |
| <65 kg | 10 mg over 1–2 min | Remainder over 2 h | Maximum 1.5 mg/kg |
Example: 60 kg → 10 mg bolus + 80 mg infusion = 90 mg total.
PE-related cardiac arrest
- Consider fibrinolysis when PE is the suspected or confirmed cause of arrest.
- Alteplase 50 mg IV bolus a further 50 mg may be considered.
- Consider continuing CPR for 60–90 minutes after thrombolysis in selected patients.
- Consider ECPR or alternative reperfusion where available.
Contraindications and monitoring
Check for major bleeding risk, including active bleeding, previous intracranial haemorrhage, recent stroke, intracranial pathology, recent major surgery or trauma, and recent anticoagulant use.
- Monitor haemodynamics, bleeding and neurological status.
- Follow local guidance for UFH interruption/resumption. The Actilyse SmPC advises starting or resuming heparin when aPTT is less than twice the upper limit of normal.
- Discuss catheter-directed or surgical reperfusion if thrombolysis is contraindicated or unsuccessful.
5. Special circumstances and disposition
- Pregnancy: use a pregnancy-specific PE pathway; LMWH is generally preferred.
- Renal impairment/contrast allergy: discuss alternative imaging and anticoagulation with radiology/specialists.
- Negative CTPA with persistent suspicion: reassess and discuss further investigation.
Consider admission for haemodynamic instability, significant oxygen requirement, RV dysfunction/myocardial injury requiring monitoring, significant comorbidity or unsafe ambulatory management.
For SDEC discharge: ensure anticoagulation supply, written bleeding/VTE advice, safety-netting and appropriate follow-up.